Innate Pharma (IPHA) with the Institute for Follicular Lymphoma, or IFLI, announced that they have entered into an agreement to clinically study the potential of IPH6501, Innate’s anti-CD20 Anket in follicular lymphoma , or FL. Innate’s ongoing Phase 1/2, open-label, multicenter trial investigating the safety, tolerability, and preliminary antineoplastic activity of IPH6501 in patients with relapsed and/or refractory CD20-expressing Non-Hodgkin Lymphoma will also include patients with relapsed / refractory FL. To support the Phase 1/2 trial and inclusion of FL patients, IFLI will initially invest $3M into new shares of Innate, issued through a capital increase reserved to IFLI at a price of EUR 1.56 per share and representing 2.26% of the share capital of Innate. IFLI may also invest up to an additional $4.9M into new shares of Innate, depending on the completion of certain milestones, at a price to be determined at the time of the said investments.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IPHA:
- Innate Pharma publishes IPH6501 data in Science Immunology
- Innate Pharma appoints Jonathan Dickinson as CEO
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
